Condition: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy · hATTR-PN · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
This description comes directly from the study's public registry record.
Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Aurora, Colorado, United States | Recruiting |
| Clinical Trial Site | Chicago, Illinois, United States | Recruiting |
| Clinical Trial Site | Baltimore, Maryland, United States | Recruiting |
| Clinical Trial Site | Boston, Massachusetts, United States | Recruiting |
| Clinical Trial Site | Rochester, Minnesota, United States | Recruiting |
| Clinical Trial Site | New York, New York, United States | Recruiting |
| Clinical Trial Site | Chapel Hill, North Carolina, United States | Recruiting |
| Clinical Trial Site | Dallas, Texas, United States | Recruiting |
| Clinical Trial Site | Houston, Texas, United States | Recruiting |
| Clinical Trial Site | Darlinghurst, Australia | Recruiting |
| Clinical Trial Site | Woolloongabba, Australia | Recruiting |
| Clinical Trial Site | Ribeirão Preto, Brazil | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223203